Pharmaceutical Technology3 天
HY-133 by HyPharm for Staphylococcal Infections: Likelihood of Approval
HY-133 is under clinical development by HyPharm and currently in Phase I for Staphylococcal Infections. According to GlobalData, Phase I drugs for Staphylococcal Infections have a 63% phase transition ...
Pharmaceutical Technology4 天
P-128 by GangaGen Biotechnologies for Staphylococcus aureus Infections: Likelihood of Approval
P-128 is under clinical development by GangaGen Biotechnologies and currently in Phase II for Staphylococcus aureus Infections.